ChemAesthetic SLU-PP 5mg

SLU-PP-332 is a synthetic small molecule agonist of the estrogen-related receptor (ERR) family, developed at Saint Louis University by Thomas Burris and colleagues. Unlike estrogen receptors, ERRs (ERRα, ERRβ, ERRγ) are orphan nuclear receptors — they lack an identified endogenous ligand — that function as master regulators of mitochondrial biogenesis and oxidative metabolism. SLU-PP-332 activates all three ERR subtypes, with published preclinical research demonstrating striking exercise-mimetic effects in rodent models.

Estrogen-Related Receptors and Metabolic Regulation

ERRα (NR3B1) and ERRγ (NR3B3) are highly expressed in metabolically active tissues — heart, skeletal muscle, brown adipose tissue, and kidney — where they regulate expression of genes involved in:

• Oxidative phosphorylation (ETC components Complexes I-V)
• Fatty acid oxidation (CPT1, HADHA, HADHB)
• Mitochondrial biogenesis (working in concert with PGC-1α)
• Tricarboxylic acid cycle enzyme expression
• Glucose metabolism and substrate switching

Exercise activates PGC-1α, which in turn co-activates ERRα — this PGC-1α/ERRα axis is a central driver of the adaptive metabolic response to endurance training. Direct ERR agonism with SLU-PP-332 bypasses the need for exercise to activate this pathway.

Preclinical Exercise Mimetic Data

Mang et al. (2023, Journal of Pharmacology and Experimental Therapeutics) published the landmark preclinical characterisation of SLU-PP-332. Key findings in rodent models:

• Daily SLU-PP-332 administration for 4 weeks significantly increased running endurance (treadmill exhaustion test) by approximately 70% versus vehicle-treated controls
• Skeletal muscle gene expression analysis showed upregulation of oxidative metabolism genes, increased Type I (slow-twitch, oxidative) fibre composition, and enhanced mitochondrial density
• Heart showed increased cardiac output capacity and reduced hypertrophic stress markers — potentially of interest in heart failure research
• Lean mass was preserved and adiposity was reduced without changes in food intake — consistent with increased metabolic rate from mitochondrial biogenesis

Mechanism: ERR vs PPARδ vs AMPK

SLU-PP-332 is often compared in research discussions to other metabolic regulators. Its mechanism differs importantly from:

• GW501516 (PPARδ agonist): Acts on peroxisome proliferator-activated receptor delta for fatty acid oxidation upregulation; distinct receptor target from ERR
• AICAR / MOTS-C (AMPK activators): Act via AMP-sensing energy signalling rather than transcriptional nuclear receptor activation
• SR9009 (Rev-ErbA agonist): Circadian clock regulation of metabolism; mechanistically distinct but overlapping metabolic outcomes

The ERR pathway's direct regulation of nuclear-encoded mitochondrial genes makes SLU-PP-332 particularly potent for mitochondrial biogenesis versus these alternatives.

Heart Failure Research Applications

Cardiac ERRα and ERRγ are downregulated in heart failure models, contributing to the metabolic shift from fatty acid oxidation to glucose utilisation that characterises failing myocardium. SLU-PP-332 and related ERR agonists are under investigation as potential therapeutic strategies for heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy — conditions with limited current treatment options.

Research Design Considerations

SLU-PP-332 has modest aqueous solubility and requires appropriate vehicle preparation (DMSO/cyclodextrin formulations are common in published protocols). Researchers should note that published preclinical data is predominantly from Burris laboratory protocols; independent replication and dose-response characterisation in specific cell/tissue models is recommended for novel research applications.